(Medical University of South Carolina) Lydex Pharmaceuticals, a startup founded by researchers at the Medical University of South Carolina and elsewhere, has received NIH funding to develop compounds for treating damage following ischemia reperfusion – the rapid reoxygenation that occurs when blood suddenly starts flowing again to a transplanted organ. By targeting histone deacetylases within the transplanted organ’s cells, the group aims to prevent ischemia-reperfusion injury, a leading cause of liver failure after transplant or major liver surgery.

Original source: https://www.eurekalert.org/pub_releases/2019-12/muos-tns120619.php